A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections

被引:7
作者
Dimopoulou, Dimitra [1 ]
Mantadakis, Elpis [2 ]
Koutserimpas, Christos [3 ]
Samonis, George [4 ,5 ]
机构
[1] Aghia Sophia Childrens Hosp, Dept Pediat 2, Athens 11527, Greece
[2] Univ Gen Hosp Alexandroupolis, Dept Pediat, Alexandroupolis 68100, Greece
[3] 251 Hellen AF Gen Hosp Athens, Dept Orthopaed & Traumatol, Athens 11525, Greece
[4] Univ Crete, Dept Med, Dept Radiol, Iraklion 71500, Greece
[5] Metropolitan Hosp, Dept Med Oncol 1, Attica 18547, Greece
来源
ANTIBIOTICS-BASEL | 2023年 / 12卷 / 10期
关键词
dalbavancin; bone and joint infections; osteomyelitis; septic arthritis; spondylodiscitis; diabetic foot infection; prosthetic joint infection; RESISTANT STAPHYLOCOCCUS-AUREUS; CLINICAL-PRACTICE GUIDELINES; ACUTE BACTERIAL SKIN; IN-VITRO ACTIVITY; ANTIBIOTIC-THERAPY; DISEASES SOCIETY; REAL-LIFE; SAFETY; PHARMACOKINETICS; VANCOMYCIN;
D O I
10.3390/antibiotics12101492
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Bone and joint infections (BJI) require prolonged antimicrobial treatment, leading to lengthy hospitalizations, high costs, the risk of nosocomial infections, and the development of antimicrobial resistance. Dalbavancin is a novel semisynthetic lipoglycopeptide approved for the treatment of adults and children with acute bacterial skin and skin structure infections. This narrative review aims to summarize the characteristics of dalbavancin and the current scientific evidence regarding its clinical efficacy and safety in the treatment of BJI. A literature search until June 2023 was performed to identify all published research about the role of dalbavancin in the management of BJI. Due to its unique pharmacokinetics characterized by prolonged half-life, high bactericidal activity against most Gram-positive bacteria, a good safety profile, and high tissue penetration, dalbavancin can be a valuable alternative to the treatment of BJI. Clinical studies have shown its non-inferiority compared to conventional therapies in BJI, offering potent activity against key pathogens and an extended dosing interval that may shorten hospitalization. In conclusion, dalbavancin represents a promising treatment option for BJI with a favorable safety profile, but further research in both adults and particularly children, who are ideal candidates for long-acting antibiotics, is necessary to evaluate the role of dalbavancin in BJI.
引用
收藏
页数:15
相关论文
共 81 条
[31]   Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic [J].
Dash, Ranjeet Prasad ;
Babu, R. Jayachandra ;
Srinivas, Nuggehally R. .
INFECTIOUS DISEASES, 2017, 49 (07) :483-492
[32]   Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy [J].
Deida, Axel A. Vazquez ;
Shihadeh, Katherine C. ;
Preslaski, Candice R. ;
Young, Heather L. ;
Wyles, David L. ;
Jenkins, Timothy C. .
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (08)
[33]   In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times [J].
Di Pilato, Vincenzo ;
Ceccherini, Federica ;
Sennati, Samanta ;
D'Agostino, Federico ;
Arena, Fabio ;
D'Atanasio, Noemi ;
Di Giorgio, Francesco Paolo ;
Tongiani, Serena ;
Pallecchi, Lucia ;
Rossolini, Gian Maria .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2020, 96 (02)
[34]   Oxazolidinone antibiotics [J].
Diekema, DJ ;
Jones, RN .
LANCET, 2001, 358 (9297) :1975-1982
[35]   French national cohort of first use of dalbavancin: A high proportion of off-label use [J].
Dinh, Aurelien ;
Duran, Clara ;
Pavese, Patricia ;
Khatchatourian, Lydie ;
Monnin, Boris ;
Bleibtreu, Alexandre ;
Denis, Eric ;
Etienne, Cedric ;
Rouanes, Nicolas ;
Mahieu, Rafael ;
Bouchand, Frederique ;
Davido, Benjamin ;
Lotte, Romain ;
Cabaret, Philippe ;
Camou, Fabrice ;
Chavanet, Pascal ;
Assi, Assi ;
Limonta, Silvia ;
Lechiche, Catherine ;
Riou, Raphaelle ;
Courjon, Johan ;
Illes, Gabriela ;
Lacassin-Beller, Flore ;
Senneville, Eric ;
Adjodah, Chandra ;
Baclet, Nicolas ;
Bouchard, Odile ;
Boutoille, David ;
Brunin, Guillaume ;
Carbognani, Daniel ;
Delobel, Pierre ;
Ferrand, Helene ;
Imbert, Yves ;
Leautez-Nainville, Sophie ;
Le Moing, Vincent ;
Loutfi, Bouchra ;
Mrozek, Natacha ;
Rouzic, Nicolas ;
Talarmin, Jean-Philippe ;
Tattevin, Pierre ;
Weyrich, Pierre .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (05) :668-672
[36]   A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection [J].
Dunne, Michael W. ;
Puttagunta, Sailaja ;
Giordano, Philip ;
Krievins, Dainis ;
Zelasky, Michael ;
Baldassarre, James .
CLINICAL INFECTIOUS DISEASES, 2016, 62 (05) :545-551
[37]   Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies [J].
Dunne, Michael W. ;
Talbot, George H. ;
Boucher, Helen W. ;
Wilcox, Mark ;
Puttagunta, Sailaja .
DRUG SAFETY, 2016, 39 (02) :147-157
[38]   Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue [J].
Dunne, Michael W. ;
Puttagunta, Sailaja ;
Sprenger, Craig R. ;
Rubino, Chris ;
Van Wart, Scott ;
Baldassarre, James .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) :1849-1855
[39]   The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections [J].
Giorgobiani, Manana ;
Burroughs, Margaret H. ;
Antadze, Tinatin ;
Carrothers, Timothy J. ;
Riccobene, Todd A. ;
Patel, Rinal ;
Lin, Tao ;
Stefanova, Penka .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2023, 42 (03) :199-205
[40]   Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age [J].
Gonzalez, Daniel ;
Bradley, John S. ;
Blumer, Jeffrey ;
Yogev, Ram ;
Watt, Kevin M. ;
James, Laura P. ;
Palazzi, Debra L. ;
Bhatt-Mehta, Varsha ;
Sullivan, Janice E. ;
Zhang, Li ;
Murphy, Jennifer ;
Ussery, Xilla T. ;
Puttagunta, Sailaja ;
Dunne, Michael W. ;
Cohen-Wolkowiez, Michael .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (07) :645-653